Clinical Trials Logo

Melanoma clinical trials

View clinical trials related to Melanoma.

Filter by:

NCT ID: NCT01515189 Completed - Melanoma Clinical Trials

Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Start date: February 17, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether giving Ipilimumab at a dose of 10mg/kg will extend the lives of subjects with unresectable or metastatic melanoma more than giving Ipilimumab at a dose of 3 mg/kg

NCT ID: NCT01512251 Completed - Clinical trials for BRAF Mutant Metastatic Melanoma

BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma

Start date: June 9, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase 1/2 clinical trial with the goal of determining whether the addition of the investigational agent BKM120 to vemurafenib will lead to improved 6-month progression-free survival in patients with BRAFV600E/K mutant melanoma.

NCT ID: NCT01511913 Completed - Clinical trials for Advanced Cutaneous Melanoma

A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma

IMAGE
Start date: June 3, 2012
Phase:
Study type: Observational

The purpose of this study is to examine the safety of Ipilimumab and patterns of use in the treatment of unresectable or metastatic melanoma in the post-approval setting

NCT ID: NCT01502293 Completed - Melanoma Clinical Trials

Trial of pIL-12 Electroporation Malignant Melanoma

IL-12MEL
Start date: February 14, 2012
Phase: Phase 2
Study type: Interventional

This study will assess the safety and effectiveness of different dosing regimens of ImmunoPulse IL-12® in malignant melanoma. ImmunoPulse IL-12® is the combination of intratumoral interleukin-12 gene (also known as tavokinogene telseplasmid [tavo]) and in vivo electroporation-mediated plasmid deoxyribonucleic acid [DNA] vaccine therapy (tavo-EP) administered using the OncoSec Medical System (OMS). ImmunoPulse IL-12® is a gene therapy approach to directly induce a pro-inflammatory response within a tumor to initiate and/or enhance anti-tumor immunity.

NCT ID: NCT01500304 Completed - Melanoma Clinical Trials

Minimally Invasive Groin Dissection for Melanoma

SAFE-MILND
Start date: June 2012
Phase: N/A
Study type: Interventional

The purpose of this this study is to determine if a structured educational training program is successful in teaching surgeons a new operative technique. It will then be determined if this new operative technique is safe.

NCT ID: NCT01497808 Completed - Metastatic Melanoma Clinical Trials

RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA

Start date: November 29, 2011
Phase: Phase 1/Phase 2
Study type: Interventional

The primary objective is to determine the maximum tolerated hypofractionated radiotherapy dose (MTD) to a solitary metastatic focus ('index lesion') when followed by ipilimumab, in metastatic melanoma patients without brain involvement The secondary objectives are to determine late toxicity, immune-related clinical responses and immune pharmacodynamic changes after hypofractionated radiotherapy followed by ipilimumab

NCT ID: NCT01489423 Completed - Melanoma (Skin) Clinical Trials

Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim

Start date: April 26, 2013
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tissue and blood in the laboratory from patients treated with ipilimumab with or without sargramostim may help doctors learn more about the effects of ipilimumab and sargramostim on cells. It may also help doctors understand how well patients respond to treatment. PURPOSE: This research trial studies tissue and blood biomarkers in patients with stage III melanoma or stage IV melanoma treated with ipilimumab with or without sargramostim.

NCT ID: NCT01489059 Completed - Melanoma Clinical Trials

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Start date: December 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine whether the combination of interleukin-21 (IL-21) and Ipilimumab in subjects with melanoma is safe, and provide preliminary information on the clinical benefits of the combination compared with Ipilimumab alone

NCT ID: NCT01482260 Completed - Clinical trials for Cutaneous Malignant Melanoma

Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

Start date: December 2011
Phase: N/A
Study type: Observational

Perturbations in microRNA (miRNA) expression profiles has been reported for cutaneous malignant melanoma (CMM). This study will be an exploratory analysis by miRNA expression profiling using microarrays.

NCT ID: NCT01480323 Completed - Malignant Melanoma Clinical Trials

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2

Start date: February 2012
Phase: Phase 2
Study type: Interventional

The current clinical trial shall clarify a synergistic effect with regards to efficiency by the combination of intratumoral injection of interleukin-2 (IL-2) and the intra-venous application of ipilimumab.